BACKGROUND: Behavioral intervention research has lagged behind biomedical research in developing principles for defining, categorizing, identifying, reporting, and monitoring adverse events and unanticipated problems. PURPOSE: In this article we present a set of principles for defining adverse events and how they were applied in a large national multi-site family therapy study for substance-using adolescents, The Brief Strategic Family Therapy (BSFT) Effectiveness Study. METHODS: The BSFT Effectiveness study tested how BSFT compares to Treatment as Usual (TAU) for the treatment of drug-abusing adolescents. During protocol development, experts in the BSFT intervention, medical safety officers, ethicists and senior investigators defined the procedures for identifying, tracking and reporting adverse events for drug using adolescents as well as their family members. During this process the team identified five key guiding principles. RESULTS: The five guiding principles that were used for defining adverse events in this behavioral trial were that that the adverse events should be validated and plausible, and that monitoring systems should assess relatedness, be systematic, and are a shared responsibility. The following non-serious adverse events were identified: arrest, school suspension and drop out, runaway, kicked out of home and violence. The serious adverse events in this study for the identified adolescent participant and all other consented family members were physical or sexual abuse, suicidal behavior, homicidal behavior, hospitalization (drug related or psychiatric related only) and death. The methods used in categorizing, identifying and reporting adverse events in the BSFT trial are outlined. More than 50% of the adolescent population (277/481 = 57.5 %) experienced an adverse event during the trial. Family members experienced less adverse events, (61/1338 = 4.5%). The most common event for the adolescent group was arrest (164/277= 59.2%), followed by school suspension/dropout (143/277 = 51.6%), and runaway (79/277= 28.5 %). For the family member group, the most common event was violence (25/ 61 = 40.9%) followed by arrest (13/61 = 21.3%). There was a significant difference in the presence of adverse events in family members that were randomized to BSFT 44/721 (6.1%) when compared to Treatment as Usual 17/617 (2.8%) (p = 0.004). A probable explanation for this is that there were more opportunities to identify adverse events for family members assigned to BSFT because family members attended therapy sessions. This difference may also represent the risk for family members that participate in an evidence-based family intervention like BSFT. LIMITATIONS: The utility of the principles outside of the BSFT trial is unknown. CONCLUSIONS: Based on the events reported in this trial, the efforts for monitoring and categorizing adverse events appeared justified and appropriate. The strategies and principles described in this paper may be useful for those developing safety plans for behavioral intervention research, and to family therapy researchers for assessing the safety of behavioral family interventions.
RCT Entities:
BACKGROUND: Behavioral intervention research has lagged behind biomedical research in developing principles for defining, categorizing, identifying, reporting, and monitoring adverse events and unanticipated problems. PURPOSE: In this article we present a set of principles for defining adverse events and how they were applied in a large national multi-site family therapy study for substance-using adolescents, The Brief Strategic Family Therapy (BSFT) Effectiveness Study. METHODS: The BSFT Effectiveness study tested how BSFT compares to Treatment as Usual (TAU) for the treatment of drug-abusing adolescents. During protocol development, experts in the BSFT intervention, medical safety officers, ethicists and senior investigators defined the procedures for identifying, tracking and reporting adverse events for drug using adolescents as well as their family members. During this process the team identified five key guiding principles. RESULTS: The five guiding principles that were used for defining adverse events in this behavioral trial were that that the adverse events should be validated and plausible, and that monitoring systems should assess relatedness, be systematic, and are a shared responsibility. The following non-serious adverse events were identified: arrest, school suspension and drop out, runaway, kicked out of home and violence. The serious adverse events in this study for the identified adolescent participant and all other consented family members were physical or sexual abuse, suicidal behavior, homicidal behavior, hospitalization (drug related or psychiatric related only) and death. The methods used in categorizing, identifying and reporting adverse events in the BSFT trial are outlined. More than 50% of the adolescent population (277/481 = 57.5 %) experienced an adverse event during the trial. Family members experienced less adverse events, (61/1338 = 4.5%). The most common event for the adolescent group was arrest (164/277= 59.2%), followed by school suspension/dropout (143/277 = 51.6%), and runaway (79/277= 28.5 %). For the family member group, the most common event was violence (25/ 61 = 40.9%) followed by arrest (13/61 = 21.3%). There was a significant difference in the presence of adverse events in family members that were randomized to BSFT 44/721 (6.1%) when compared to Treatment as Usual 17/617 (2.8%) (p = 0.004). A probable explanation for this is that there were more opportunities to identify adverse events for family members assigned to BSFT because family members attended therapy sessions. This difference may also represent the risk for family members that participate in an evidence-based family intervention like BSFT. LIMITATIONS: The utility of the principles outside of the BSFT trial is unknown. CONCLUSIONS: Based on the events reported in this trial, the efforts for monitoring and categorizing adverse events appeared justified and appropriate. The strategies and principles described in this paper may be useful for those developing safety plans for behavioral intervention research, and to family therapy researchers for assessing the safety of behavioral family interventions.
Authors: Robert M Califf; Michael A Morse; Janet Wittes; Steven N Goodman; Daniel K Nelson; David L DeMets; R Peter Iafrate; Jeremy Sugarman Journal: Control Clin Trials Date: 2003-06
Authors: Panagiotis N Papanikolaou; Rachel Churchill; Kristian Wahlbeck; John P A Ioannidis Journal: Am J Psychiatry Date: 2004-09 Impact factor: 18.112
Authors: Scott W Henggeler; W Glenn Clingempeel; Michael J Brondino; Susan G Pickrel Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-07 Impact factor: 8.829
Authors: Michael S Robbins; José Szapocznik; Viviana E Horigian; Daniel J Feaster; Marc Puccinelli; Petra Jacobs; Kathy Burlew; Robert Werstlein; Ken Bachrach; Greg Brigham Journal: Contemp Clin Trials Date: 2009-01-18 Impact factor: 2.226
Authors: Diana Harris; Linda Patrick-Miller; Lisa Schwartz; John Lantos; Chris Daugherty; Mary Daly; Irene L Andrulis; Saundra S Buys; Wendy K Chung; Caren J Frost; Esther M John; Theresa H M Keegan; Julia A Knight; Mary Beth Terry; Angela R Bradbury Journal: J Adolesc Health Date: 2014-05-17 Impact factor: 5.012
Authors: Harald Baumeister; Natalie Bauereiss; Anna-Carlotta Zarski; Lina Braun; Claudia Buntrock; Christian Hoherz; Abdul Rahman Idrees; Robin Kraft; Pauline Meyer; Tran Bao Dat Nguyen; Rüdiger Pryss; Manfred Reichert; Theresa Sextl; Maria Steinhoff; Lena Stenzel; Lena Steubl; Yannik Terhorst; Ingrid Titzler; David Daniel Ebert Journal: Front Psychiatry Date: 2021-05-14 Impact factor: 4.157
Authors: Arik V Marcell; Sara B Johnson; Tim Nelson; Alain B Labrique; Kathryn Van Eck; Sara Skelton; Anushka Aqil; Dustin Gibson Journal: J Health Care Poor Underserved Date: 2021
Authors: Jiaxi Lin; Lasse Sander; Sarah Paganini; Sandra Schlicker; David Ebert; Matthias Berking; Jürgen Bengel; Stephanie Nobis; Dirk Lehr; Oskar Mittag; Heleen Riper; Harald Baumeister Journal: BMJ Open Date: 2017-12-28 Impact factor: 2.692